Validation of a highly sensitive RP-HPLC method for quantification of fenofibrate in pure and pharmaceutical dosage forms

Current Pharmaceutical Analysis

Volumn 10, Issue 2, 2014, Pages 97-104

  Yousaf, Abid Mehmood ^a   Kim, Dong Wuk ^a   Choi, Han Gon ^a   Oh, Euichaul ^b  

^a Hanyang University   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Acetonitrile; Dosage form; Fenofibrate; RP HPLC; Validation

Indexed keywords

FENOFIBRATE;

ACCURACY; ARTICLE; DRUG DEGRADATION; DRUG DOSAGE FORM; DRUG STABILITY; EVAPORATION; FLOW RATE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TEMPERATURE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84899831123     PISSN: 15734129     EISSN: 1875676X     Source Type: Journal    
DOI: 10.2174/1573412910999140113115903     Document Type: Article

References (27)

1. Munoz, A.; Guichard, J. P.; Reginault, P. Micronised fenofibrate. Atherosclerosis, 1994, 110(0), S45-S48.
2. Granero, G. E.; Ramachandran, C.; Amidon, G. L. Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev. Ind. Pharm., 2005, 31(9), 917-922.
3. Adkins, J.; Faulds, D. Micronised Fenofibrate. Drugs, 1997, 54(4), 615-633.
4. Balfour, J.; McTavish, D.; Heel, R. Fenofibrate. Drugs, 1990, 40(2), 260-290.
5. Genest, J. J.; Nguyen, N.-H.; Theroux, P.; Davignon, J.; Cohn, J. S. Effect of Micronized Fenofibrate on Plasma Lipoprotein Levels and Hemostatic Parameters of Hypertriglyceridemic Patients with Low Levels of High-Density Lipoprotein Cholesterol in the Fed and Fasted State. J. Cardiovasc. Pharmacol., 2000, 35(1), 164-172.
6. Guay, D. Micronized fenofibrate: a new fibric acid hypolipidemic agent. The Ann. Pharmacother., 1999, 33(10), 1083-1103.
7. Kosoglou, T.; Statkevich, P.; Fruchart, J.-C.; Pember, L. J.; Reyderman, L.; Cutler, D. L.; Guillaume, M.; Maxwell, S. E.; Veltri, E. P. Pharmacodynamic and pharmaco-kinetic interaction between fenofibrate and ezetimibe*. Curr. Med. Res. Opin®., 2004, 20(8), 1197-1207.
8. Packard, C. Overview of fenofibrate. Eur. Heart J., 1998, 19, A62-65.
9. Filippatos, T.; Milionis, H. J. Treatment of hyperlipidaemia with fenofibrate and related fibrates. Expert Opin. Investig. Drugs, 2008, 17(10), 1599-1614.
10. Shi, G. Q.; Dropinski, J. F.; Zhang, Y.; Santini, C.; Sahoo, S. P.; Berger, J. P.; MacNaul, K. L.; Zhou, G.; Agrawal, A.; Alvaro, R. Novel 2, 3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARα agonists with potent hypolipidemic activity. J. Med. Chem., 2005, 48(17), 5589-5599.
11. Lacroix, P. M.; Dawson, B. A.; Sears, R. W.; Black, D. B.; Cyr, T. D.; Ethier, J.-C. Fenofibrate raw materials: HPLC methods for assay and purity and an NMR method for purity. J. Pharm. Biomed. Anal., 1998, 18(3), 383-402.
12. Doser, K.; Guserle, R.; Nitsche, V.; Arnold, G. Comparative steady state study with 2 fenofibrate 250 mg slow release capsules. An example of bioequivalence assessment with a highly variable drug. Int. J. Clin. Pharmacol. Ther., 1996, 34(8), 345-348.
13. Kadav, A.; Vora, D. Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets. J. Pharm. Biomed. Anal., 2008, 48(1), 120-126.
14. El-Gindy, A.; Emara, S.; Mesbah, M. K.; Hadad, G. M. Spectrophotometric and liquid chromatographic determination of fenofibrate and vinpocetine and their hydrolysis products. Il Farmaco, 2005, 60(5), 425-438.
15. Hernando, M. D.; Petrovic, M.; Fernández-Alba, A.; Barceló, D. Analysis by liquid chromatography-electrospray ionization tandem mass spectrometry and acute toxicity evaluation for β-blockers and lipid-regulating agents in wastewater samples. J. Chromatogr. A., 2004, 1046(1), 133-140.
16. Komsta, Ł.; Misztal, G.; Majchrzak, E.; Hauzer, A. Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals. J. Pharm. Biomed. Anal., 2006, 41(2), 408-414.
17. Shihabi, Z. K. Fenofibrate and fenofibric acid analysis by capillary electrophoresis. Electrophoresis, 2004, 25(10-11), 1648-1651.
18. Yardi{dotless}mci{dotless}, C.; Özalti{dotless}n, N. Electrochemical studies and square-wave voltammetric determination of fenofibrate in pharmaceutical formulations. Anal. Bioanal. Chem., 2004, 378(2), 495-498.
19. VIPUL, K.; Rajshree, M. Simultaneous quantitative resolution of atorvastatin calcium and fenofibrate in pharmaceutical preparation by using derivative ratio spectrophotometry and chemometric calibrations. Anal. Sci., 2007, 23(4), 445-451.
20. ICH Guidelines. Quality Guidelines. Analytical Validation Q2. Validation of Analytical Procedures: Text and Methodology Q2(R1). http://www. ich. org/products/guidelines/quality/article/quality-guidelines. html (Accessed Dec 17, 2013).
21. Salama, F. M.; Nassar, M. W.; El-Din, M. M. S.; Attia, K. A.; Kaddah, M. Y. Determination of fenofibrate and the degradation product using simultaneous UV-derivative spectrometric method and HPLC. Am. J. Anal. Chem., 2011, 2, 332-343.
22. Wabaidur, S.; Mohsin, K.; Alothman, Z. Development of a Stability Indicating UPLC-MS/MS Method for Rapid and Reliable Determination of Fenofibrate in Marketed Product (Lypanthyl 200M) and Human Plasma. J. Pharm. Drug. Dev., 2013, 1(1), 1.
23. Ming-Thau, S.; Ching-Min, Y.; Sokoloski, T. D. Characterization and dissolution of fenofibrate solid dispersion systems. Int. J. Pharm., 1994, 103(2), 137-146.
24. Vogt, M.; Kunath, K.; Dressman, J. B. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur. J. Pharm. Biopharm., 2008, 68(2), 283-288.
25. Shabir, G. A. Validation of high-performance liquid chromatography methods for pharmaceutical analysis: Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. J. Chromatogr. A., 2003, 987(1-2), 57-66.
26. Niessen, W. M. A.; Tinke, A. P. Liquid chromatography-mass spectrometry General principles and instrumentation. J. Chromatogr. A., 1995, 703(1-2), 37-57.
27. Choi, B. K.; Hercules, D. M.; Gusev, A. I. Effect of liquid chromatography separation of complex matrices on liquid chromatography-tandem mass spectrometry signal suppression. J. Chromatogr. A., 2001, 907(1-2), 337-342.